Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life. (3rd July 2021)

• Record Type: Journal Article
• Authors: Eikeland, Siri A.; Smeland, Knut B.; Mols, Floortje; Fagerli, Unn-Merete; Bersvendsen, Hanne S.; Kiserud, Cecilie E.; Fosså, Alexander
• Is Part Of: Acta oncologica. Volume 60:Number 7(2021)
• Page Start: 911
• Page End: 920
• Publication Date: 2021-07-03
• Subjects: Adverse effects -- chemotherapy-induced peripheral neuropathy -- Hodgkin's lymphoma survivor -- cancer survivorship; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2021.1917776
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin's lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL). Material and methods: A questionnaire, including EORTC QLQ-CIPN-20 for CIPN related symptoms and SF-36 for HRQoL, was completed by 303 HL survivors at a median of 16 years after diagnosis. CIPN results were compared to a normative population ( n = 606). CIPN associated factors were identified by linear regression analysis. Results: Total CIPN score and subscores were significantly higher in HL survivors compared to controls. In multivariate analysis of HL survivors, a number of comorbidities ( p < 0.001) and female gender ( p = 0.05) were significantly associated with more CIPN. No association with disease or treatment factors was found. In a multivariate analysis including survivors and controls, the number of comorbidities ( p < 0.001) and caseness ( p < 0.001) were significantly associated with more CIPN. In HL survivors higher CIPN score was associated with reduced HRQoL ( p < 0.001). Conclusion: HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy.